Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||ovary serous adenocarcinoma||not applicable||Cediranib + Olaparib||Phase II||Actionable||In a Phase II trial, Cediranib (AZD-2171) and Lynparza (olaparib) treatment was well-tolerated, and resulted in an objective response (OR) of 9% (all partial), a 16-week progression-free survival (PFS) of 47%, and a disease control rate (DCR) of 68% in serous ovarian cancer patients (n=34), with an OR of 0%, 20%, 8%, 16-week PFS of 55%, 50%, 39%, and a DCR of 82%, 60%, 62% in platinum-sensitive (n=11), platinum-resistant (n=10), and exploratory cohorts (n=13), respectively (PMID: 32444417; NCT02681237).||32444417|